PubMed HealthSearch

Biomedical subjects

L Seipel

Publications and source records attributed to L Seipel.

At least 37 records · Page 2Linked to original sources

[Hemodynamic effects of disopyramide on postischemic and normal myocardium].

The acute effects of i.v. disopyramide (1.5 mg/kg) on the hemodynamics of postischemic hearts were investigated in comparison to normal ventricles. Infusion (7 min) was started in rats 20 min after 3 x 4 min of global ischemia during the period of stable postischemic dysfunction. 15 minutes after disopyramide i.v. (vs. NaCl control data) the cardiac output was reduced to 82 +/- 4% (vs. 101 +/- 5%; p less than 0.01) and dp/dtmax to 77 +/- 5% (vs. 83 +/- 3%). The maximum isovolumic pressure generating capacity as load-independent index of myocardial contractility was reduced to 89 +/- 2% (vs. 95 +/- 2%; p less than 0.05). In contrast to the results on postischemic myocardium no measureable change of the hemodynamics was detectable after the identical dose in normal animals without left ventricular dysfunction. Our results indicate an increased sensitivity of postischemic myocardium with modestly reduced contractile function to the hemodynamic effects of disopyramide, especially to the negative-inotropic effects.

Animals

Doppler measurement of cardiac output across prosthetic mitral valves.

In 46 patients with a normal functioning mitral valve prosthesis (15 St. Jude, 19 Medtronic Hall, 12 Hancock) cardiac output was measured by pulsed Doppler echocardiography across the valve prosthesis. Simultaneously cardiac output was determined by thermodilution or pulsed Doppler echocardiography in the left ventricular outflow tract (2.8 l/min-9.5 l/min). The prosthetic valve area was calculated using the pressure half-time method. Cardiac output was calculated by multiplying time-velocity integrals with the mitral valve area. Cardiac output measurements across the mitral prosthesis correlated significantly with thermodilution (r = 0.96, SEE = 0.400 l/min) and pulsed Doppler echocardiography flow measurements in the left ventricular outflow tract (r = 0.82, SEE = 0.679 l/min). The mean percent error of the Doppler transmitral flow measurement was 10.8%. Doppler transmitral flow underestimated cardiac output valves of more than 6.5 l/min in 6 of 7 patients. Cardiac output measurements across Hancock (SEE = 0.473 l/min) and St. Jude prostheses (SEE = 0.538 l/min) were more accurate than across Medtronic Hall prostheses (SEE = 0.847 l/min). Cardiac output can be calculated by pulsed Doppler echocardiography across normal functioning mitral prostheses. Due to the different flow dynamics the accuracy of cardiac output measurement depends on the prosthetic valve type. Reliable measurements of cardiac output can be performed across Hancock and St. Jude prostheses only. This method is limited in volume flow measurements across Medtronic Hall prostheses.

Adult

Electrophysiologic effects and efficacy of cibenzoline on stimulation-induced atrial fibrillation and flutter and implications for treatment of paroxysmal atrial fibrillation.

The effects of intravenous cibenzoline (1.5 mg/kg) on atrial vulnerability and electrophysiology were assessed in 25 patients with documented paroxysmal atrial fibrillation (AF), in whom sustained (greater than 30 seconds) AF was induced by atrial stimulation with up to 2 extrastimuli and paced rates between 100 and 180 beats/min. In 7 patients AF persisted despite the application of cibenzoline, and in 8 patients the induction of sustained AF was prevented by cibenzoline. Intraatrial conduction time, flutter cycle length and shortest ventricular cycle length during AF were increased by cibenzoline (p less than or equal to 0.01). Sinus cycle length was decreased (p less than or equal to 0.05), whereas sinus node recovery time remained unchanged. The effective refractory period of the right atrium was not significantly affected. Eight patients with frequent episodes of paroxysmal AF received oral cibenzoline for control of paroxysmal AF irrespective of the efficacy of intravenous cibenzoline. Prevention of stimulation-induced AF predicted successful treatment of paroxysmal AF (p = 0.018). Cibenzoline could be effective in the treatment of atrial arrhythmias, and selection of an antiarrhythmic therapy for recurrent AF seems to be useful.

Administration, Oral

[Low-dose enalapril as additional medication in severe chronic heart failure].

A prospective, randomized efficacy study of low-dose enalapril was undertaken in 38 outpatients (24 men, 14 women; mean age 58 [41-69] years) with chronic heart failure (NYHA functional class III-IV). All patients were pretreated with digitalis and diuretics, some also with conventional vasodilators. 19 patients (group E) received in addition to their previous medication, 5 mg enalapril daily, while the other 19 (group K) continued with their previous therapy. Three months later, 15 patients in group E improved by at least one NYHA functional class and none died (P less than 0.02). Four patients in group K died and only one patient improved by one class. After three months, left ventricular ejection fraction was significantly higher (P less than 0.0001) in group E (39 +/- 19%) compared to group K (30 +/- 14%). In group E, plasma aldosterone concentration decreased significantly (P less than 0.0001) by 33.4 +/- 6.5 ng/dl, while in group K no significant change occurred (delta 1.1 +/- 1.2 ng/dl). Thus, low-dose enalapril in addition to conventional therapy may improve the clinical status of patients in severe chronic heart failure. This improvement is associated with an increase in left ventricular ejection fraction and reduction in secondary hyperaldosteronism.

Chi-Square Distribution

AV nodal reentrant tachycardia using three different AV nodal pathways.

In a patient with frequent paroxysmal supraventricular tachycardia, an electrophysiologic study was performed. Although by programmed atrial stimulation only double AV nodal pathways could be documented, three distinct forms of AV nodal reentrant tachycardia could be induced. By programmed atrial stimulation a typical AV nodal reentrant tachycardia was initiated, by programmed ventricular stimulation, an AV nodal reentrant tachycardia was induced with an antegrade conduction time of 215 ms and a retrograde conduction time of 160 ms. Furthermore, a third form of tachycardia was induced with alternating cycle length due to two different antegrade conduction times, whereas retrograde conduction time was almost identical, irrespective of the antegrade conduction time. The patient received betaxolol (20 mg day-1); during a second electrophysiologic study, the tachycardia could not be induced, and it did not occur spontaneously during a follow-up period of 14 months.

Atrioventricular Node

Effects of intravenous cibenzoline on ventricular vulnerability and electrophysiology in patients with sustained ventricular tachycardia in comparison to a control group.

The electrophysiologic effects of intravenous (i.v. 1.5 mg/kg) cibenzoline were investigated in 13 patients with organic heart disease and supraventricular arrhythmias (control group) and 13 patients with drug refractory sustained ventricular tachycardia (VT group). In both groups, cibenzoline increased the effective refractory period (ERP) of the right ventricle (p less than or equal to 0.05), QRS duration (p less than or equal to 0.01), and QTc duration (p less than or equal to 0.01). Cycle length of the VT was increased from 311 +/- 73 to 393 +/- 119 ms (p less than or equal to 0.05) as well. The increase in QTc duration was more pronounced (p less than or equal to 0.05) in the VT group as compared with the control group. In four patients in the VT group with the largest increase in QRS-, QTc duration and cycle length of the VT proarrhythmia was noted after i.v. cibenzoline. Cibenzoline plasma levels were not significantly different between the two study groups. In the VT group, induction of VT was prevented in 2 patients, more difficult in 2 patients, easier in 1 patient, and unchanged in 5 patients. Spontaneous occurrence of the VT or induction by atrial stimulation was noted in 4 patients. In the control group, ventricular vulnerability remained unchanged. Cibenzoline may be effective in selected patients with drug refractory VT. In such patients, the increase in QTc duration was more pronounced as compared with a control group.

Anti-Arrhythmia Agents

Percutaneous coronary excimer laser angioplasty in patients with stable and unstable angina pectoris. Acute results and incidence of restenosis during 6-month follow-up.

A clinical study was conducted to evaluate the efficacy and safety of percutaneous coronary excimer laser angioplasty in 60 patients with coronary artery disease. Forty-nine patients had stable exertional angina, and 11 patients had unstable angina despite medical therapy. A novel 1.4-mm diameter catheter with 20 quartz fibers of 100-microns diameter each arranged concentrically around a central lumen suitable for a 0.014-in. flexible guide wire was coupled to an excimer laser. A commercial excimer laser emitting energy at a wavelength of 308 nm with a pulse duration of 60 nsec was used. The laser was operated at 20 Hz. Mean energy transmission was 30 +/- 5 mJ/mm2. In five of the 60 patients, laser angioplasty was not attempted. In 23 patients with laser ablation alone, percent stenosis decreased from 76 +/- 14% before to 27 +/- 17% after ablation and was 34 +/- 15% at the early follow-up angiogram. In 32 patients, additional balloon angioplasty was performed because of vessel closure after laser ablation in 11 and an insufficient qualitative result in 21 patients. Of the 11 patients with unstable angina, one patient died due to vessel closure 3 hours after intervention, and two patients developed a myocardial infarction. In 22 of 47 patients with late follow-up angiography, restenosis within the 6-month follow-up period occurred. Rate of restenosis was higher in patients treated with laser ablation and balloon angioplasty (16 of 28) than in patients treated with laser ablation alone (six of 19). These results suggest that coronary excimer laser angioplasty for ablation of obstructive lesions is feasible and safe in patients with stable angina. However, development of new catheter systems is necessary for an improved success rate.

Adult

[Electrophysiologic effects of penticainide in patients with supraventricular tachycardia].

The electrophysiologic effects of the new class-I antiarrhythmic drug pentisomide were investigated after intravenous (5 mg/kg) application in nine patients with atrioventricular nodal reentrant tachycardia and six patients with atrioventricular tachycardia. Pentisomide did not change sinus cycle length, effective refractory period of the right ventricle (ERP-RV), the AV-node (ERP-AVN) and QT interval. Intranodal (AH-interval) and infranodal conduction time (HV-interval), effective refractory period of the right atrium (ERP-A), QRS duration, antegrade effective refractory period of the accessory pathway (ERP-Kent), ventricular cycle length during atrial fibrillation and tachycardia cycle length were significantly (P less than 0.05) increased. Intravenous pentisomide prevented induction of the tachycardia in 5/9 patients with atrioventricular nodal tachycardia and in 2/6 patients with atrioventricular tachycardia. The electrophysiologic properties of pentisomide indicate that it might be a useful drug in the treatment of supraventricular tachycardia.

Adult

[Negative inotropic effect of flecainide on the post-ischemic heart with limited contractile function].

The hemodynamic effects of 7 min i.v. flecainide were examined in rats with postischemic left ventricular dysfunction. For quantification of contractile function the isovolumic left ventricular pressure generating capacity and dp/dtmax were determined. Fifteen min after infusion the isovolumic maximum pressure was reduced for 33 mm Hg after flecainide (2 mg/kg; n = 12), whereas in the controls only a minimal reduction (12 mm Hg; n = 13) was found; dp/dtmax was also significantly reduced after flecainide. The results indicate - in contrast to prior investigations on normal hearts - a considerable negative action of 2 mg/kg flecainide i.v. on postischemic myocardium with reduced contractile function.

Animals

[Electrophysiologic effects of the calcium antagonist isradipine, a double-blind placebo controlled study].

The electrophysiologic effects of the calcium channel antagonist isradipine (0.5 mg) in comparison to placebo were evaluated in a double blind study with nine patients in two groups. The patient groups were not different in respect to the underlying cardiac disease, electrophysiologic parameters at the baseline study, or in blood pressure. Isradipine significantly decreased the systolic (p less than 0.01) and diastolic (p less than 0.05) blood pressure, while sinus cycle length decreased significantly (p less than 0.05) in the placebo group and the isradipine group with no difference between the two study groups. The influence on sinus node recovery time, effective refractory period of the av-node, intranodal conduction time, and PR interval were not significant. In conclusion, isradipine significantly decreased systolic and diastolic blood pressure. The decrease in sinus cycle length after intravenous isradipine was not significantly different from the decrease seen in the placebo group. Atrioventricular conduction was not significantly affected.

Atrioventricular Node

[Anti-tachycardia surgery in ventricular arrhythmia].

UNLABELLED: Recurrent sustained ventricular tachycardia (VT) is associated predominantly with ischemic heart disease, mostly in the chronic phase after myocardial infarction. Potentially life-threatening and drug-refractory ventricular tachycardias are called malignant VT. In the Federal Republic of Germany, VT develops in about 3,000 to 5,000 patients per year from the 100,000 who survive a myocardial infarction. About 10% of these patients prove to be medically-refractory or additionally are considered candidates for aneurysmectomy or coronary revascularization. Overall, for the Federal Republic of Germany, there is a need for approximately 500 to 1000 antitachycardia operations each year. The morphologic substrate for malignant VT are ischemically-damaged inhomogeneously-structured arrhythmogenic areas. The morphology results in electrical inhomogeneity which predisposes to electrophysiologic reentry phenomena. NATURAL HISTORY: The survival rate of patients with malignant VT who are not surgically treated is 70% at one year and 20 to 40% at four years (Figure 1). In those in whom the tachycardia can be medically controlled, the prognosis is 10.5 times more favorable than in those with medically-refractory arrhythmias. In one study of 45 patients with recurrent, sustained VT, only 20% of those with medical refractoriness were free of renewed arrhythmic events after 30 weeks as compared to 90% whose treatment had been designated effective (p less than 0.0004) (Figure 2). According to a further study, for patients with drug-refractory VT, the probability for sudden death within four years was 55% as compared with 5% for those with medically-controlled VT (p less than 0.0002). SURGICAL TREATMENT: The concept of surgical treatment of malignant VT encompasses delineation of the arrhythmogenic area by means of endocardial mapping and surgical ablation. Arrhythmogenic areas are located mostly in the transition zone between the viable muscle and an aneurysm at the left ventricular endomyocardial septum. With mapping, by means of local measurements of activity times, impulse spread throughout the heart can be recorded in a cartographic system. The left ventricular endocardial activation should be determined during sinus rhythm and tachycardia and, with normothermic extracorporeal circulation the left ventricle is incised, mostly in the aneurysmatic antero-apical area, prior to sequential interrogation of the endocardial surface (Figure 3). As an alternative to point-for-point mapping, by means of multi-terminal electrodes, electrocardiograms can be obtained simultaneously from multiple positions. During tachycardia, the earliest activation can be found in the arrhythmogenic area (Figure 4); during sinus rhythm, in these areas, delayed, low-amplitude and fragmented signals are present (Figure 5). Macroscopically, endomyocardial fibrosis is a common finding. The arrhythmogenic morphologic substrate is either reduced or rendered a homogeneous scar without electrical activity. In this regard, techniques for endomyocardial resection have been described by Harken and Josephson. As an alternative procedure. Guiraudon introduced the encircling endomyocardial resection with which the pathologic reentry circuit can be blocked and the microvascular blood flow to arrhythmogenic areas eliminated. One modification, the partial encircling resection, appears to yield comparable effectiveness with less damage to left ventricular function (Figure 6).(ABSTRACT TRUNCATED AT 400 WORDS)

Electrocardiography

[Percutaneous coronary excimer laser angioplasty].

Available preliminary clinical studies have shown that ablation of atherosclerotic plaques can be achieved by means of pulsed excimer laser coronary angioplasty via flexible energy transmission systems. The goal of current studies using improved catheter technology is to enhance the acute success rate since, based on initial studies, it can be assumed that only about 40 to 45% of the patients can be successfully treated. The on-going investigations were carried out primarily with three different excimer laser systems which employ a wavelength of 308 nm but differing pulse widths and transmission systems. In the first American multicenter study by Litvack and Margolis a catheter system was used with a pulse width of 180 to 220 ns. The fibers have a shaft diameter of 100 microns with a conically-thickened distal end measuring 200 microns, the ablative area encompasses 35 to 45% of the total catheter tip surface. The excimer laser used in the second American multicenter study by Sanborn and Isner has a pulse width of 120 ns. This catheter is relatively unflexible due to the 200 microns fiber diameter. The ablative catheter tip area is 25 to 30%. In Tübingen a system was used with a pulse width of 60 ns. The energy is transmitted through fibers with a diameter of 100 microns. The effective ablative area in the first series of patients was about 15%, in the second series about 25 to 30%. At present, the energy density of all three systems is comparable with at least 25 to 35 mJ/mm2. Since there is currently no means for accurate assessment, the question of whether a shorter pulse width of comparable energy density is more effective than the longer pulse width, remains an open issue. The flexibility of the systems used by Margolis and in Tübingen enable ablation not only of proximal, but also arteriosclerotic plaques located in the middle-third of vessels. The flexibility and steerability, however, are inferior to balloon catheter systems. In the study carried out by Litvack and Margolis, in which more than 600 patients have been treated, and the results from 514 patients reported, there was no patient selection in the first series. The study by Sanborn and Isner included 88 patients. Due to the relatively unflexible catheter system, only those patients were treated who had proximal stenosis of the left anterior descending or right coronary artery or marginal branches of the circumflex artery without marked tortuosity.(ABSTRACT TRUNCATED AT 400 WORDS)

Angioplasty, Balloon, Coronary

[Effect of cibenzoline on atrial vulnerability and value of electrophysiological methods in the treatment of paroxysmal atrial fibrillation].

The effects of intravenous cibenzoline (1,5 mg/kg) on atrial vulnerability and electrophysiology were assessed in 25 patients with documented paroxysmal atrial fibrillation, in whom sustained (greater than 30 s) atrial fibrillation/-flutter was induced by programmed atrial stimulation. In seven patients atrial fibrillation persisted despite the application of cibenzoline; in eight patients induction of atrial fibrillation was not prevented. In 10 patients the induction of sustained atrial fibrillation was prevented by cibenzoline. Intraatrial conduction time and shortest ventricular cycle length during atrial fibrillation were increased by cibenzoline (p less than or equal to 0.01). The effective refractory period of the right atrium was not significantly affected. Eight patients with frequent episodes of paroxysmal atrial fibrillation received oral cibenzoline (320 mg/day) for control of paroxysmal atrial fibrillation irrespective of the efficacy of intravenous cibenzoline. Prevention of stimulation-induced atrial fibrillation predicted successful treatment of paroxysmal AF. In conclusion, cibenzoline might be effective in the treatment of atrial tachyarrhythmias. Programmed atrial stimulation seems to be helpful in the prediction of the efficacy of an antiarrhythmic treatment of paroxysmal atrial fibrillation.

Adult

[Percutaneous coronary Excimer laser angioplasty in patients with coronary heart disease].

To verify the efficacy and safety of percutaneous coronary excimer laser angioplasty in patients with coronary artery disease a prospective study was conducted in 60 patients. The application of laser light was possible in 55 of the 60 patients. A novel 1.4-mm diameter catheter with 20 quartz fibers of 100-microns diameter, each arranged concentrically around a central lumen suitable for an 0.014-inch flexible guide wire was used. The light source was a commercial excimer laser emitting energy at a wavelength of 308 nm, with a pulse duration of 60 ns. The laser was operated at 20 Hz; mean energy transmission was 30 +/- 5 mJ/mm2. In 23 of the 55 patients treated with excimer laser energy the qualitative angiographic results were sufficient. In 32 patients additional balloon angioplasty was necessary, either because of an insufficient result or due to vessel closure after laser ablation. In 47 of the 55 patients control angiography was performed within the 6-month follow-up period. Rate of restenosis was higher in patients treated with laser ablation and subsequent balloon angioplasty (16 of 28) than in patients treated with laser ablation alone (6 of 19). Results of the 6-month observation period suggest that 1) coronary excimer laser angioplasty in combination with subsequent balloon angioplasty results in a considerable increase of the restenosis rate; 2) the exclusive use of laser ablation also results in a restenosis rate comparable to balloon angioplasty alone; and 3) the impact of this new method using improved application systems and higher energy transmission has to be determined in further studies.

Angina Pectoris

Hemodynamic effects of antiarrhythmic drugs: negative inotropy versus influence on peripheral circulation.

The negative inotropic effect of nearly all antiarrhythmic drugs is one of the major drawbacks in antiarrhythmic therapy. This is particularly important in patients with reduced left ventricular function. In the clinical setting, different compounds have been described to depress cardiac function to a variable extent. The results are not uniform. In an experimental model, the hemodynamic effects of different drugs in the intact circulation as well as under isovolumic conditions in vivo after short cross-clamping of the aorta were tested. The results indicate that all antiarrhythmic compounds with the exception of class III drugs have a similar negative inotropic action on the heart muscle. However, the drugs have different effects on peripheral resistance, thus influencing cardiac afterload. These differences seem to be responsible for the different hemodynamic effects of the drugs observed clinically.

Animals